Ueda Tomoaki, Fukushima Kentaro, Kusakabe Shinsuke, Yoshida Koki, Suga Makiko, Nakai Ritsuko, Koike Midori, Hino Akihisa, Akuta Keigo, Toda Jun, Nagate Yasuhiro, Doi Yukiko, Fujita Jiro, Yokota Takafumi, Hosen Naoki
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan.
Laboratory of Cellular Immunotherapy, World Premier Interenational Immunology Frontier Research Center, Osaka University.
Leuk Res Rep. 2022 Feb 15;17:100294. doi: 10.1016/j.lrr.2022.100294. eCollection 2022.
To overcome the unfavorable outcome of refractory/relapsed (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and conduct allogeneic stem cell transplantation (allo-SCT) safely, we designed a sequential therapy involving a single cycle of Inotuzumab ozogamicin (InO) and Blinatumomab (Blina). Two heavily treated and aged patients with R/R Ph+ALL were treated with the therapy. Both of them achieved complete molecular remission without cytokine release syndrome and underwent allo-SCT without veno-occlusive disease/sinusoidal obstruction syndrome. Although appropriate central nervous system prophylaxis should be added, the InO-Blina sequential therapy is a promising strategy for treating R/R Ph+ALL as a bridging regimen before allo-SCT.
为克服难治性/复发性（R/R）费城染色体阳性急性淋巴细胞白血病（Ph+ALL）的不良预后并安全进行异基因干细胞移植（allo-SCT），我们设计了一种序贯疗法，包括单周期的奥英妥珠单抗（InO）和博纳吐单抗（Blina）。两名经过多次治疗的老年R/R Ph+ALL患者接受了该疗法治疗。他们均实现了完全分子缓解，无细胞因子释放综合征，并在没有发生静脉闭塞性疾病/窦性阻塞综合征的情况下接受了allo-SCT。尽管应添加适当的中枢神经系统预防措施，但InO-Blina序贯疗法作为allo-SCT前的桥接方案，是治疗R/R Ph+ALL的一种有前景的策略。
